The company reported that Acuvue Oasys Max 1-Day and Oasys 1-Day outperformed the other 5 daily disposable lenses evaluated in a recent study, among other Johnson & Johnson data highlights at AAOpt 2026.
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Advertisement
Related to this article
Three residents were honored for their leadership, education and research, and patient care contributions in ophthalmology, optometry, and retina.
Andrew Pucker, OD, PhD, FAAO, FSLS, FBCLA, discussed how oculomics research presented at AAOpt 2026 could eventually support point-of-care diagnosis and referral decisions.
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.
Sherrol Reynolds, OD, FAAO, details her session "GLP-1RAs and Ocular Health: AOA Guidance for Optometric Practice 2025" during AAOpt 2026.
A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.
Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Optimizing the ocular surface for cataract/refractive surgery: A case study
2
What is the biggest barrier to eye care access worldwide?
3
AAOpt 2026: Photobiomodulation to revolutionize dry AMD treatment, Dr Rafieetary says
4
AAOpt 2026: Brimonidine-hyaluronic acid drop sustains redness relief through 10 hours
5